Mestastop Solutions applies to the CDSCO for approval of a Phase II clinical trial targeting metastasis.

(Isstories Editorial):- Bengaluru, Karnataka May 16, 2025 (Issuewire.com) – Bangalore-based biotech Mestastop Solutions, which focuses on cancer metastasis, has filed for approval of its first clinical candidate for a Phase II study to delay metastasis in adjuvant settings for patients with primary colorectal cancer tumours.

Founded in 2018, the company has dedicated significant time to understanding metastasis biology using primary tumour patient samples in collaboration with the Rajiv Gandhi Cancer Institute. This effort involves close collaboration with Dr. (Col) Anurag Mehta, Dr. D.C. Doval, and Dr. Juhi Tayal. Mestastop conducted both prospective and retrospective studies with Rajiv Gandhi to identify the current clinical candidate. Speaking on this, Dr. (Col) Anurag Mehta, MD, Pathology and Director of Laboratory, Molecular Diagnostics and Transfusion Services at Rajiv Gandhi, said, ” Metastasis is the principal cause of cancer mortality and the greatest obstacle to curative treatment. Unravelling its underlying biology and identifying biomarkers that can intercept the spread from the primary site could redefine cancer management, shifting the focus from damage control to true disease containment. I am pleased that Mestastop has chosen this critical field to direct its resources.”

Mestastop is collaborating on this trial with Raptim Research, a Mumbai-based contract research organisation (CRO). Raptim has conducted over 50 late-stage trials in multiple therapeutic areas and has also cleared more than nine US FDA inspections for late-phase oncology trials. Dr. Chirag Shah, Head of Clinical and Business Operations at Raptim Research, added, “We are highly excited to associate with Mestastop at this important juncture of their growth trajectory, as the founder’s dream is coming into reality, as we are progressing towards clinical evaluation after extensive lab work of more than five years. Since our association, we have been highly impressed and motivated by the vision carried by the founders for treating ailing patients through their discovery. We have also understood the deep science and innovative work they are carrying out  and wish them grand success.”

More on Isstories:

• Get A 15% Discount on Real YouTube Promotion Service from Video Promotion Club
• Atua AI Expands Modular Frameworks to Enhance Multichain Coordination
• New York Attorney Michael Collesano Named in Foreclosure Filing
• Edmonton Agency Mavericks Edge Uses AI to Bring Enterprise-Level Digital Services to Local SMBs
• John Adeiza, FNP-C: Delivering Compassionate Care with Restore Medical Group

Mestastop aims to conduct this trial on sixty primary colorectal cancer patients who have undergone surgery and/or chemotherapy. The randomized controlled, double-blinded trial is expected to run for at least two years, and the company intends to initiate patient recruitment as soon as approval is received. Dr. Arnab Roy Chowdhury, founder and director of Mestastop, said that “the novelty of the Mestastop approach in preventing cells from colonizing in the secondary axis has a tremendous potential to impact how we treat cancer, and we all believe that this will help a lot of patients in the future. I thank all our clinicians and partners for supporting us through this long and tedious journey.”

2025 has been an eventful year for Mestastop. Two of its initial patents have been approved in India and the USA, and the company has also filed for two new international patents for its two potential clinical candidates. It is currently working on a novel discovery program with a first-in-class target for metastasis and will present new data at the upcoming European Association of Cancer Research meeting in June 2025.

This article was originally published by IssueWire. Read the original article here.